VEGF and Liver Tumor

Vascular Endothelial Growth Factor (VEGF) is a key protein involved in the development and progression of liver tumors, especially hepatocellular carcinoma (HCC), which is the most common type of primary liver cancer. VEGF promotes angiogenesis, the formation of new blood vessels, which is critical for tumor growth, invasion, and metastasis. It binds to specific receptors, such as VEGFR-2, to stimulate endothelial cell proliferation, vascular remodeling, and increased vascular permeability. This process provides oxygen and nutrients to the tumor, enabling its rapid growth.

In liver tumors like HCC, VEGF is often overexpressed, especially under hypoxic conditions (low oxygen), which are common in growing tumors. Hypoxia triggers the release of VEGF through the activation of Hypoxia-Inducible Factor-1α (HIF-1α). VEGF also contributes to portal vein tumor thrombosis (PVTT), a severe complication in HCC, and promotes the spread of secondary liver tumors (metastases) by enhancing vascularization.

VEGF is not only a marker of poor prognosis, as its high levels correlate with larger tumors, vascular invasion, and metastasis, but it also serves as a major therapeutic target. Anti-VEGF therapies have transformed the treatment of advanced liver tumors. Examples include bevacizumab, a monoclonal antibody targeting VEGF-A, and tyrosine kinase inhibitors (TKIs) like sorafenib and lenvatinib, which block VEGF receptors and other angiogenic pathways. Combination therapies, such as atezolizumab (anti-PD-L1) and bevacizumab, have shown superior efficacy in managing advanced HCC by combining VEGF inhibition with immune checkpoint blockade.

Despite their benefits, VEGF-targeted therapies face challenges like resistance (activation of alternative angiogenic pathways) and toxicity (e.g., hypertension, bleeding). Future directions focus on developing predictive biomarkers to select the right patients, combining VEGF inhibitors with other treatments, and personalizing therapies based on tumor profiles.

In summary, VEGF plays a central role in liver tumor biology, and targeting it has become a cornerstone of treatment, particularly for advanced HCC. However, ongoing research aims to address resistance and improve outcomes through innovative strategies.